Latest Oncology News

Pilot Program Improves Palliative Care Training for Hematology/Oncology Fellows

December 25th 2024

Kyle Doherty

The director of the Hematology/Oncology Fellowship Training Program at Fox Chase Cancer Center discusses palliative care training for hematology/oncology fellows and highlights a pilot study aimed at improving this area of training.

Novel Therapies and Combinations Augment Melanoma Treatment Arsenal

December 25th 2024

Kyle Doherty

Omid Hamid, MD, discusses recent advances in the melanoma treatment landscape and highlights the 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

December 24th 2024

Bradley D. Hunter, MD

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC

December 24th 2024

Chris Ryan

European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.

Rewriting the Rules for a Better Future of Cancer Care

December 24th 2024

Brielle Benyon

Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in diversifying clinical trials and improving quality of life.

Latest Oncology Videos

Summary of Recent Advances and Unmet Needs for Patients With eBC

Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi

Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma

Initial Approach to Management of RET-Positive NSCLC

Key Takeaways for Concurrent Biomarker Testing in NSCLC

Practice Takeaways: Treating MF Patients—Key Strategies for Community Providers

Optimizing PARP Inhibitor Duration

Multidisciplinary Treatment Sequencing and Coordination

Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results

Sarting with a Patient Case: 45yM high-risk T4N0 resected CRC - What are next steps?

CAR T-cell Therapy for B-ALL

Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) for Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Results of a Global Randomized Phase III Trial (STARGLO)

Key Considerations When Ordering Biomarker Testing

Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets

Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer

Defining Resectability in Stage III NSCLC: Addressing Key Controversies

Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis

Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.

Introduction and Incidence of HPV-Positive Head and Neck Cancer

Deep and Sustained Responses in Patients With CLL Treated With Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report From the Zanubrutinib Extension Study

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007

Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease

All Oncology News

Combination Regimens Make Their Mark in Frontline HCC

December 24th 2024

Kyle Doherty

In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.

Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma

December 23rd 2024

Kyle Doherty

Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

December 23rd 2024

Courtney Flaherty

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC

December 23rd 2024

Megan Hollasch

Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.

Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD

December 23rd 2024

Philippe Moreau, MD

Dr Moreau highlights key findings on MRD negativity dynamics from IMROZ and their future implications for patients with newly diagnosed multiple myeloma.

Understanding Graft-VS-Host Disease (GVHD) Basics

December 23rd 2024

Panelists discuss how graft-vs-host disease (GVHD) is a complex immune-mediated condition, highlighting the differences between acute and chronic GVHD, the associated risk factors, prognosis, and the impact of increased cyclophosphamide use on the clinical presentation of the disease.

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

December 23rd 2024

Ashling Wahner

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer

December 23rd 2024

Chris Ryan

The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.

FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC

December 23rd 2024

Chris Ryan

The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

UC Davis Researchers Help Decode the Cause of Aggressive Breast Cancer in Women of Color

December 23rd 2024

UC Davis Comprehensive Cancer Center

Findings point to a biomarker that may give a “head start” to triple-negative breast cancer in Black women.

Initial Treatment Strategies for Polycythemia Vera

December 23rd 2024

Andrew Kuykendall, MD

Panelists discuss how they approach the evaluation and diagnosis of polycythemia vera (PV), including key clinical manifestations, and how they assess disease risk to determine initial treatment strategies based on NCCN guidelines, considering factors that differentiate low-risk from high-risk PV.

Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL

December 23rd 2024

Lori A. Leslie, MD

Meta: Lori A Leslie, MD, discusses 5-year follow-up data from the ZUMA-5 trial evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

December 23rd 2024

Kristi Rosa

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

Insights on the LANCE Pilot Study on Lung LCNEC

December 23rd 2024

Martin Dietrich, MD, PhD

Panelists discuss their impressions of the LANCE pilot study for atezolizumab in lung large cell neuroendocrine carcinoma (LCNEC) and its potential impact on treatment strategies.

The Role of DLL3 in LCNEC of the Lung

December 23rd 2024

Martin Dietrich, MD, PhD

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

See All News